EX-12.1 13 dex121.txt STATEMENT REGARDING THE COMPUTATION OF CONSOLIDATED RATIO Exhibit 12.1 Teva Pharmaceutical Industries Limited Computation of ratio of earnings to fixed charges (U.S. dollars in millions, except total earnings to fixed charges)
Nine Months Ended September 30, Year ended December 31, ------------- ---------------------------------------------------- 2003 2002 2001 2000 1999 1998 ------------- -------- -------- -------- -------- -------- (unaudited) ------------- Fixed charges: Interest costs (expensed and capitalized) and amortization of issuance costs relating to long-term debentures $ 39.2 $ 54.7 $ 47.3 $ 53.8 $ 35.2 $ 30.4 Rentals - one third of rental expense (the portion deemed representative of the interest factor) 3.3 4.6 4.5 2.5 2.5 1.8 ------------- -------- -------- -------- -------- -------- Total fixed charges $ 42.5 $ 59.3 $ 51.8 $ 56.3 $ 37.7 $ 32.2 ============= ======== ======== ======== ======== ======== Earnings: Pre-tax income from continuing operations before adjustment for minority interests in consolidated subsidiaries or income or loss from equity investees $ 636.8 $ 499.4 $ 340.3 $ 208.4 $ 162.0 $ 98.8 Fixed charges, as above 42.5 59.3 51.8 56.3 37.7 32.2 Amortization of capitalized interest, less interest capitalized 0.9 0.8 0.7 0.2 0.3 0.6 ------------- -------- -------- -------- -------- -------- Total earnings $ 680.2 $ 559.5 $ 392.8 $ 264.9 $ 200.0 $ 131.6 ============= ======== ======== ======== ======== ======== Total earnings to fixed charges 16.00 9.43 7.58 4.70 5.30 4.09 ============= ======== ======== ======== ======== ========